BLM and breast carcinoma: Therefore, we tested LN229- WT, RQ4 KO or BLM KO cells responses to WP744, the 4’-O-benzylated doxorubicin analogue, inhibiting DNA topoisomerase II and triggering apoptosis in breast cancer, acute myeloid leukemia, neuroblastoma cells and human glioma stem cells [16, 25].